Search Results

There are 62360 results for: content related to: Heart rate decrease during crizotinib treatment and potential correlation to clinical response

  1. You have free access to this content
    Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

    British Journal of Pharmacology

    Volume 166, Issue 5, July 2012, Pages: 1669–1683, Wen-jing Zhou, Xu Zhang, Chao Cheng, Fang Wang, Xiao-kun Wang, Yong-ju Liang, Kenneth Kin Wah To, Wang Zhou, Hong-bing Huang and Li-wu Fu

    Version of Record online : 21 JUN 2012, DOI: 10.1111/j.1476-5381.2012.01849.x

  2. Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

    The Oncologist

    Volume 17, Issue 11, November 2012, Pages: 1351–1375, Sai-Hong Ignatius Ou, Cynthia Huang Bartlett, Mari Mino-Kenudson, Jean Cui and A. John Iafrate

    Version of Record online : 18 SEP 2012, DOI: 10.1634/theoncologist.2012-0311

  3. Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer

    International Journal of Cancer

    Volume 140, Issue 9, 1 May 2017, Pages: 1945–1954, Candice C. Poon and John J. Kelly

    Version of Record online : 20 JAN 2017, DOI: 10.1002/ijc.30533

  4. You have free access to this content
    ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

    Cancer

    Volume 120, Issue 16, August 15, 2014, Pages: 2392–2402, Conor E. Steuer and Suresh S. Ramalingam

    Version of Record online : 22 MAY 2014, DOI: 10.1002/cncr.28597

  5. You have full text access to this OnlineOpen article
    Complex renal cysts associated with crizotinib treatment

    Cancer Medicine

    Volume 4, Issue 6, June 2015, Pages: 887–896, Patrick Schnell, Cynthia H. Bartlett, Benjamin J. Solomon, Vanessa Tassell, Alice T. Shaw, Tommaso de Pas, Soo-Hyun Lee, Geon Kook Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, Keith D. Wilner, Allan Safferman and Ji-Youn Han

    Version of Record online : 10 MAR 2015, DOI: 10.1002/cam4.437

  6. You have free access to this content
    Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

    International Journal of Cancer

    Volume 134, Issue 6, 15 March 2014, Pages: 1484–1494, Seng Chuan Tang, Luan N. Nguyen, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen and Alfred H. Schinkel

    Version of Record online : 3 OCT 2013, DOI: 10.1002/ijc.28475

  7. You have free access to this content
    Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer

    Cancer

    Volume 118, Issue 21, 1 November 2012, Pages: 5302–5309, Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman and D. Ross Camidge

    Version of Record online : 4 APR 2012, DOI: 10.1002/cncr.27450

  8. Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 15–23, B Solomon, KD Wilner and AT Shaw

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.200

  9. You have free access to this content
    Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients

    Cancer

    Volume 119, Issue 13, 01 July 2013, Pages: 2383–2390, Andrew J. Weickhardt, Robert C. Doebele, W. Thomas Purcell, Paul A. Bunn, Ana B. Oton, Micol S. Rothman, Margaret E. Wierman, Tony Mok, Sanjay Popat, Julie Bauman, Jorge Nieva, Silvia Novello, Sai-Hong Ignatius Ou and D. Ross Camidge

    Version of Record online : 12 APR 2013, DOI: 10.1002/cncr.28089

  10. You have full text access to this OnlineOpen article
    Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

    Chemical Biology & Drug Design

    Volume 78, Issue 6, December 2011, Pages: 999–1005, Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson and Victor M. Rivera

    Version of Record online : 31 OCT 2011, DOI: 10.1111/j.1747-0285.2011.01239.x

  11. You have full text access to this OnlineOpen article
    Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors

    Cancer Science

    Volume 108, Issue 1, January 2017, Pages: 53–60, Hirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, Takayuki Nakagawa, Sachiko Arai, Shigeki Nanjo, Tadaaki Yamada, Hiroyuki Yamaguchi, Hiroshi Mukae and Seiji Yano

    Version of Record online : 30 DEC 2016, DOI: 10.1111/cas.13111

  12. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

    The Journal of Clinical Pharmacology

    Volume 55, Issue 1, January 2015, Pages: 104–113, Huiping Xu, Melissa O'Gorman, Tanya Boutros, Nicoletta Brega, Constantino Kantaridis, Weiwei Tan and Akintunde Bello

    Version of Record online : 10 JUL 2014, DOI: 10.1002/jcph.356

  13. Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase

    Molecular Informatics

    Volume 34, Issue 2-3, February 2015, Pages: 105–114, Anish Kumar, V. Shanthi and K. Ramanathan

    Version of Record online : 30 JAN 2015, DOI: 10.1002/minf.201400070

  14. You have full text access to this OnlineOpen article
    Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma

    Thoracic Cancer

    Volume 7, Issue 1, January 2016, Pages: 3–8, Quan Zhang, Na Qin, Jinghui Wang, Jialin Lv, Xinjie Yang, Xi Li, Jingying Nong, Hui Zhang, Xinyong Zhang, Yuhua Wu and Shucai Zhang

    Version of Record online : 23 APR 2015, DOI: 10.1111/1759-7714.12264

  15. You have full text access to this OnlineOpen article
    Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients

    Cancer Medicine

    Volume 5, Issue 6, June 2016, Pages: 1013–1021, Shaohua Cui, Yizhuo Zhao, Lili Dong, Aiqin Gu, Liwen Xiong, Jialin Qian, Wei Zhang, Yanjie Niu, Feng Pan and Liyan Jiang

    Version of Record online : 16 FEB 2016, DOI: 10.1002/cam4.659

  16. You have full text access to this OnlineOpen article
    Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK

    Cancer Medicine

    Volume 4, Issue 7, July 2015, Pages: 953–965, Diletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini and Luca Mologni

    Version of Record online : 26 FEB 2015, DOI: 10.1002/cam4.413

  17. You have full text access to this OnlineOpen article
    Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer

    Cancer Science

    Ryohei Katayama

    Version of Record online : 15 FEB 2018, DOI: 10.1111/cas.13504

  18. Targeting ALK Rearrangements

    Lung Cancer, Fourth Edition

    Justin F. Gainor, Alice T. Shaw, Pages: 541–556, 2014

    Published Online : 4 APR 2014, DOI: 10.1002/9781118468791.ch35

  19. Met interacts with EGFR and Ron in canine osteosarcoma

    Veterinary and Comparative Oncology

    Volume 11, Issue 2, June 2013, Pages: 124–139, J. K. McCleese, M. D. Bear, S. K. Kulp, C. Mazcko, C. Khanna and C. A. London

    Version of Record online : 8 DEC 2011, DOI: 10.1111/j.1476-5829.2011.00309.x

  20. You have free access to this content
    Hypogonadism related to crizotinib therapy

    Cancer

    Volume 118, Issue 21, 1 November 2012, Pages: E1–E2, Suresh S. Ramalingam and Alice T. Shaw

    Version of Record online : 4 APR 2012, DOI: 10.1002/cncr.27561